Send to

Choose Destination
Autoimmun Rev. 2012 Aug;11(10):771-5. doi: 10.1016/j.autrev.2012.02.012. Epub 2012 Feb 22.

The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA).

Author information

INOVA Diagnostics, INC. San Diego, CA 32131-1638, USA.


Autoantibodies targeting the proliferating cell nuclear antigen (PCNA) were first described over 30 years ago and are historically most commonly associated with systemic lupus erythematosus (SLE). The primary antigenic target is a 34 kDa protein that is part of the DNA polymerase delta multi-protein complex. A number of diagnostic platforms have incorporated PCNA into their diagnostic assays and algorithms. However, little is known about the clinical utility of autoantibodies to PCNA, especially with novel detection systems. This review will focus on the history of the discovery of the PCNA autoantigen and the current status of the diagnostic significance of anti-PCNA and suggest future studies that are required to strengthen our understanding of their clinical utility.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center